natgillin/translations-raw huggingface dataset:
The pharmaceutical composition according to claim 1 or 2, wherein at least one peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1, pri čemu navedeni peptid uključuje nepeptidne veze.
an antiviral agent or a pharmaceutically acceptable salt thereof; or 
[image] ili njegova farmaceutski prihvatljiva sol ili ester, naznačen time, da:
The use of claim 7, wherein said ADAM is selected from fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer. 
Uporaba prema zahtjevu 7, naznačena time da je navedeno stanje ADAM odabrano iz skupa koji čine umor, depresija, smanjeni libido, seksualna disfunkcija, erektilna disfunkcija, hipogonadizam, osteoporoza, gubitak kose, anemija, pretilost, sarkopenija, osteopenija, osteoporoza, benigna hiperplazija prostate, promjene u raspoloženju i spoznaji i karcinom prostate.
The inventors have found out that it is actually more efficient to empty the thermoblock from the inlet side and at the same time venting air to the outlet side of the corresponding thermoblock. 
Izumitelji su uočili da je zapravo učinkovitije isprazniti termoblok s izlazne strane uz istodobno propuhivanje zraka na izlaznoj strani odgovarajućeg termobloka.
A capsule according to clause 21 or 22, wherein the further ridge comprises a conical section on an inner circumferential surface thereof. 
Kapsula (2) prema zahtjevu 21 ili 22, naznačena time, da dodatni greben (40) obuhvaća stožasti dio na njegovoj unutarnjoj obodnoj površini (44).
The use of claim 10, wherein the disorder or disease is selected from the group consisting of cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. 
Uporaba prema patentnom zahtjevu 10, naznačena time što je poremećaj 1li bolest izabran/izabrana iz grupe koju čine poremećaji i bolesti srca, poremećaji i bolesti skeletnih mišića, kognitivni poremećaji 1 bolesti, maligna hipertermija, dijabetes i sindrom iznenadne smrti novorođenčeta.
R1a is and R2 is and P is a protecting group, with a reducing agent followed by deprotection. 
a je, je, a P je zaštitna skupina, s reducensom nakon uklanjanja zaštite.
The pharmaceutical composition of clause 2, wherein the salt is montelukast sodium and the corresponding sulfoxide is the sulfoxide of formula (I): 
Farmaceutska kompozicija prema patentnom zahtjevu 2, naznačena time što je sol montelukast natrij i odgovarajući sulfoksid je sulfoksid formule (I):
A compound according to any of claims 1 to 42, wherein R6 is H and R6' is H, (C1-C6)alkyl or (C3-C8)cycloalkyl. 
. Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 42, naznačen time što Rs je H i Rs'je H, (C,-Cs)alkil ili (Ca-
the first antibody H chain variable region consists of SEQ ID NO: 45; the second antibody H chain variable region consists of SEQ ID NO: 52; and the first and second antibody L chain variable regions each consist of SEQ ID NO: 62. 
(c6) mjesto vezanja antigena koje obuhvaća aminokiselinsku sekvencu varijabilnog područja L-lanca od SEQ ID NO: 61 (varijabilno područje L-lanca od L377); (c7) mjesto vezanja antigena koje obuhvaća aminokiselinsku sekvencu varijabilnog područja L-lanca od SEQ ID NO: 62 (varijabilno područje L-lanca od L404);
A method for the preparation of a composite according to claim 1, comprising the step of contacting a metakaolin support and titanium dioxide, or one of its precursors, to have them bonded by thermal treatment. 
Postupak pripreme kompozita prema jednom ili više prethodnih zahtjeva, a koji obuhvaća korak omogućavanja recipročnog kontakta između metakaolina i titanijevog dioksida ili jednog od njegovih prekursora.
One preferred embodiment of R is formula (I) shown below. 
R predstavlja bilo koju formulu od (I) do (VIII):
a VH region comprising the amino acid sequence of SEQ ID NO:4 and a VL region comprising the amino acid sequence of SEQ ID NO: 7; 
Protutijelo ili njegov fragment koji veže a-sinuklein u skladu s patentnim zahtjevom 1, naznačen time da VH regija obuhvaća aminokiselinske odsječke od SEQ ID NO: 9 i VL regija sadržava aminokiselinske odsječke od SEQ ID NO: 12.
HPLC Retention Time (in minutes) 
[retencije (ulpriprave minutama)
W is hydrogen, halogen, amino, hydroxy, thiol, alkyl, substituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfonyl, CF3, NO2, CN, N3, sulfonyl, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, or substituted cycloalkyl; 
W je vodik, halogen, amino, hidroksi, tiol, alkil, supstituirani alkil, supstituirani ili nesupstituirani alkoksi, supstituirani ili nesupstituirani alkilamino, supstituirani ili nesupstituirani dialkilamino, supstituirani ili nesupstituirani alkiltio, supstituirani ili nesupstituirani alkilsulfonil, CF3, NO2, CN, N3, sulfonil, acil, aril, supstituirani aril, heteroarii, supstituirani heteroaril, heterocikal, supstituirani heterocikal, eikloalkil, ili supstituirani eikloalkil;
The organic portion is separated and washed brine (50 ml), dried (MgS04) and concentrated in vacuo. 
Organski dio se odvoji 1 ispere sa zas. otop. NaCl (50 ml), osuši (MgSO;) i koncentrira u vakuumu.
an anion exchange chromatography 
anionska izmjenjivačka kromatografija,
The starting compound of the formula: 
Datum podnošenja europske prijave patenta:
with quinine: and ethyl alcohol to form an adduct of the quinine and Compound (C-1): 
s kininom i etil-alkoholom kako bi se dobilo adukt kinina sa Spojem (C-1):
The solvent was removed under reduced pressure. 
Otapalo se ukloni pri sniženom tlaku.
A process for preparing an oil-in-water emulsion, comprising the steps of: (a) obtaining squalene that has been purified from a yeast that produces a high yield of squalene during culture; and (b) combining the squalene purified of step (a) with an aqueous component to form the oil-in-water emulsion. 
Postupak za dobivanje adjuvanta emulzija ulja u vodi, naznačen time da sadrži korake: dobivanje skvalena koji je pročišćen od kvasca koji daje visok prinos skvalena tijekom kultivacije, pri čemu je kvasac uzgojen u kontroliranom mediju bez proizvoda životinjskog podrijetla; te
a step of storing thermal energy received from the solar radiation concentrated by said first portion (31) of bed (3) of particles; and 
koraka pohranjivanja toplinske energije sunčevog zračenja koncentriranog navedenim prvim dijelom (31) sloja (3) čestica i
In a preferred embodiment the aqueous pharmaceutical formulation also comprises 0.1 µg to 10 µg lixisenatide per U insulin glargine. 
Vodena formulacija u skladu s patentnim zahtjevom 2, naznačena time što sadrži 0,1 ug do 10 ug liksisenatida po jedinici inzulin glargina.
The pharmaceutical composition according to claim 9, which is the platelet production regulating agent. A crystal of ethyl 3-(4-carboxy-2,6-dichlorophenyl)-2-methylacrylate having a diffraction angle 2θ of a main peak of powder X-ray diffraction of 8.1, 16.3, 19.2, 20.0, 24.8, and 39.0 degrees, wherein the X-ray diffraction measurement conditions are as follows: vacuum tube CuK a-ray, tubular voltage 40kV, tubular current 40mA or 50mA. 
Kristal etil 3-(4-karboksi-2,6-diklorofenil)-2-metilakrilata naznačen time da ima glavni vršak kod difrakcije X-zraka na prahu s kutom difrakcije 2θ kod 8.1, 16.3, 19.2, 20.0, 24.8, i 39.0 stupnjeva, pri čemu su uvjeti mjerenja difrakcije X-zraka kako slijedi: vakuumska cijev CuK a-zraka, napon rendgenske cijevi 40kV, struja rendgenske cijevi 40mA ili 50mA.
The method of claim 1, wherein the frozen G-CSF composition is stored in step (c) over a period of at least two days. 
Postupak prema bilo kojem zahtjevu od 1 do 7, naznačen time, da se zamrznuti G-CSF-sastav u koraku (c) pohranjuje u vremenskom periodu od najmanje tri mjeseca.
A method according to any of numbered embodiments 1 to 9, further comprising providing a fiberising chamber and collector means comprising a conveyor in the base of the chamber; collecting the blown fibres as a web and carrying them away from the set of rotors. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 9, nadalje sadrži upotrebu komore za izradu vlakana i jedinice za skupljanje koja sadrži transporter u dnu te komore, prikupljanje puhanih vlakana u obliku tkanine i njihovo uklanjanje iz sklopa rotora.
A preferred compound of the invention is the compound the preparation of which is specifically described in example 1. 
Poželjni spoj prema ovom izumu je spoj, čije dobivanje je specifično opisano u Primjeru 1.
The soft chewable veterinary composition of claim 26, wherein the macrocyclic lactone is eprinomectin, ivermectin selamectin, milbemectin, milbemycin D, milbemycin oxime, or moxidectin, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 26, naznačen time, da makrociklički lakton je eprinomektin, ivermektin, selamektin, milbemektin, milbemicin D, milbemicin oksim ili moksidektin, ili njihova kombinacija.
Use of an infant and/or toddler nutrition according to any of embodiments 1-15 for the manufacture of a composition for providing nutrition to an infant and/or toddler. 
Uporaba hrane za dojenčad i/ili dijete prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je za proizvodnju pripravka za osiguravanje prehrane za dojenčad i/ili dijete.
A compound of formula (X): 
Spoj naznačen time da ima formulu (X): o
Even more preferred, the second binding domain specific for human CEA comprises at least the amino acid sequence “RFYFDY” (SEQ ID NO. 113), “LRFYFDY” (SEQ ID NO. 114), “GLRFYFDY” (SEQ ID NO. 
(b) drugu vežuću domenu koja se specifično veže na ljudski CEA, gdje navedena druga vežuća domena specifična za ljudski CEA sadrži (i) CDR-HI koji ima aminokiselinski slijed "SYWMH" (SEQ ID NO.
The use of claim 11, wherein the cardiac disorders and diseases are selected from the group consisting of irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure, preferably wherein the irregular heartbeat disorders and diseases and exercise-induced irregular heartbeat disorders and diseases are selected from the group consisting of atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. 
Spoj prema patentnom zahtjevu 12, naznačen time što su poremećaji i bolesti nepravilnog srčanog rada i poremećaji i bolesti nepravilnog srčanog rada indcirani pojačanom fizičkom aktivnošću izabrani iz grupe koju čine atrijalna 1 ventrikularna aritmija; atrijalna i ventrikularna fibrilacija; atrijalna i ventrikularna tahiaritmija; atrijalna 1 ventrikularna tahikardija; kateholaminergična polimorfna ventrikularna tahikardija (CPVT); i njihove varijante izazvane pojačanom fizičkom aktivnošću.
A fiber cement product comprising at least one profiled surface obtained according to any one of the preceding claims. 
Vlaknasti cementni proizvod, naznačen time što sadrži najmanje jednu profiliranu površinu dobivenu prema bilo kojem od prethodnih patentnih zahtjeva.
The method of claim 1, wherein the presentation score is a p-value of a linear mixed model or a p-value of a t-test. 
Metoda prema bilo kojem zahtjevu od 1 do 8, gdje je prezentacijski rezultat veličina p linearnog mješovitog modela ili veličina p t-testa.
The compound according to claim 1, wherein the compound has formula I-G wherein, independently for each occurrence: 
8. - Spoj prema patentnom zahtjevu 1, pri čemu je spoj formule I-G O
The lithium oxygen battery according to claim 1, further comprising a separator, wherein the separator is preferably located between the lithium anode and the porous cathode current collector. The lithium oxygen battery according to claim 1, further comprising a pump, wherein said pump circulates the catholyte in the battery. 
Litij kisik baterija prema bilo kojem od patentnih zahtjeva 1 do 8, koja dalje sadrži razdvajač (8), gdje se razdvajač poželjno nalazi između litijske anode (7) i poroznog katodnog strujnog kolektora (9), poželjno koja dalje sadrži pumpu (4), gdje navedena pumpa cirkulira katolit u bateriji.
The method of claim 1 further comprising the step of generating a magnetic field within the chamber with quasi-dc coils extending about the chamber and a mirror magnetic field within opposing ends of the chamber with quasi-dc mirror coils extending about the opposing ends of the chamber. 
generiranje magnetskog polja unutar komore s kvazi-DC zavojnicama (412) koje se protežu oko komore, ili b) generiranje zrcalnog magnetskog polja unutar suprotnih krajeva komore s kvazi-DC zrcalnim zavojnicama (420) koje se protežu oko suprotno položenih krajeva komore.
The biocompatible implant according to claim 9 wherein said metal, metal alloy or metal oxide is titanium. 
Biokompatibilni usadak u skladu s patentnim zahtjevom 8, naznačen time što je navedeni metal, metalna legura ili metalni oksid titanij.
The pharmaceutical composition according to claim 5, wherein the anti-HCV agent is an immunomodulatory agent selected from a-, B-, δ- Y-, t- and w-interferon and pegylated forms thereof. 
Farmaceutski sastav prema zahtjevu 15, naznačen time, da je sljedeće anti-HCV-sredstvo jedno imunomodulacijsko sredstvo odabrano od ae, 3-, 8-Y-, T- i o-interferona te od njihovih pegiliranih oblika.
comprising the operation step in which at least one liquid spraying component (240), the flow control kit (252) and liquid supply kit (250) is controlled by at least one control unit (260), 
- sadrži korak postupka u kojem najmanje jedna komponenta (240) raspršivanja tekućine, komplet (252) za upravljanje protokom i komplet (250) za dovod tekućine se kontrolira uz pomoć najmanje jedne upravljačke jedinice (260),
A kit comprising: a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, or a cell according to claim 6, in solution or in lyophilized form; and 
(a) Kutije koja sadrži farmaceutski sastav koji se sastoji od peptida u skladu s bilo kojim zahtjevom 1 - 4, nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, stanice u skladu s patentnim zahtjevom 7 ili 8, ili aktiviranog citotoksičnog T-limfocita u skladu s patentnim zahtjevom 11, u otopini ili liofiliziranom obliku; i
The method according to claim 1, wherein the compound is one selected from the following group: 
Antitijelo-lijek konjugat u skladu sa patentnim zahtjevom 2, gdje je segment strukture lijek-veznik jedna lijek-veznik struktura odabrana od sljedeće grupe:
A process for preparing a compound as claimed in claim 1, the process comprising the following steps: by reacting a compound of formula (XIV): 
Postupak dobivanja spoja u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u sljedećim koracima: reakcije spoja formule (II): t>&
Telescopic mast according to any of claims 1 - 6, characterised in that a cable (11) is provided inside the telescoping sections (3,4,5). 
Teleskopski stup u skladu s bilo kojim od patentnih zahtjeva 1 - 6, karakteriziran na način da je kabel (11) omogućen unutar teleskopskih odjeljaka (3, 4, 5).
The invention has the further object of providing a wireless remote control system for a boat, wherein the system alerts the user when radio communication between a hand-held wireless remote control device, and a receiver, has been interrupted. 
Izum ima daljnji cilj omogućiti bežični daljinski kontrolni sustav za plovilo, pri čemu sustav upozorava korisnika kad se prekine radio veza između ručnog bežičnog daljinskog upravljačkog uređaja i prijemnika.
is selected from the group consisting of 
R! je odabrano iz skupine koja se sastoji od 9,
The genetically modified mouse of claim 1, wherein the mouse further comprises in its genome an endogenous k light chain immunoglobulin locus comprising a replacement of endogenous Vk and Jk gene segments with unrearranged human Vλ and Jλ gene segments, and wherein the human Vλ and Jλ gene segments are operably linked to an endogenous mouse Ck gene such that the mouse expresses an immunoglobulin light chain that comprises a human λ variable region fused with a mouse k constant region. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-B-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 13, wherein 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-B-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof is administered daily. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 13, gdje navedeni anti-CTLA4 je administriran otprilike svaka tri tjedna.
A compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein R4 is n-propyl, isopropyl, or tert-butyl. 
Spoj u skladu s patentnim zahtjevom 12, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R4 je n-propil, izopropil ili tert-butil.
(C2-C5)-alkylene-heterocycloalkyl, wherein said heterocycloalkyl is selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-azepanyl, 4-morpholinyl 1,1-dioxo-thiomorpholin-4-yl, and 1-piperazinyl; wherein said heterocycloalkyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of (C1-C2)alkyl, or methylene-phenyl; 
(C2-C5)-alkilen-heterocikloalkil, pri čemu je navedeni heterocikloalkil odabran iz skupine koju čine 1-pirolidinil, 1-piperidinil, 1-azepanil, 4-morfolinil 1,1-diokso-tiomorfolin-4-il, i 1-piperazinil; pri čemu je navedeni heterocikloalkil nesupstituiran ili supstituiran s 1 ili 2 supstituenta odabrana iz skupine koju čine (C1-C2)alkil, ili metilen-fenil;
A pharmaceutical composition comprising an antibody of any one of claims 1-4. or 6. 
Farmaceutski sastav koji uključuje antitijelo temeljem bilo kojeg od zahtjeva 1-4, ili 6.
The compound of Claim 2, or a pharmaceutically acceptable salt thereof, wherein the compound of formula 1.0 is a compound of formula 1.3, and Q is selected from the group consisting of: 2.1, 2.2, and 2.3, and 2.3 is selected from the group consisting of: and R3, R4, R6, and R7 are each independently selected from the group consisting of: H and alkyl. 
[image] Spoj prema patentnom zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, pri čemu, spoj formule 1.0 je spoj formule 1.3, i Q je izabran iz grupe koju čine: 2.1, 2.2 i 2.3, i 2.3 je izabran iz grupe koju čine:
Use of the pharmaceutical composition according to any one of claims 1 to 12 as an anti-cancer vaccine. A kit comprising: 
Farmaceutski sastav prema zahtjevu 10, naznačeno time da je spomenuti adjuvans čimbenik stimulacije rasta kolonije.
The topical veterinary composition of claim 1 wherein the carrier comprises a C1-C12 dialkyl ester of the dicarboxylic acid. 
Topikalni veterinarski pripravak prema zahtjevu 1, naznačen time, da nosač obuhvaća C;-Cy-dialkilester od dikarboksilne kiseline.
albumin-binding small molecules; 
(h) malih molekula koje vežu albumin;
a gradient calculating device configured to calculate magnitude and a direction of gradient of a pixel value for each pixel of the band image; an isotropic blurring device configured to apply an isotropic smoothing filter to the original image to generate an isotropic blur image; 
(C) uređaj za izotropno zamagljenje (14) koji ima konfiguraciju za nanošenje izotropnog filtera za omekšavanje šuma na originalnu sliku (PO) u svrhu stvaranja izotropne zamagljene slike (P1);
Use of a duplex stainless steel of according to any of claims 1 or 2, wherein Mn is of from 0.5-1.5 wt%, wherein Si is of from 0.010 to 0.50 wt%, wherein Ni is of from 5.5 to 8.5 wt% and wherein N is of from 0.28 to 0.40 wt%. 
Upotreba dupleks nehrđajućeg čelika u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačena time što se Mn kreće od 0.5-1.5 mas%, gdje se Si kreće od 0.010 do 0.50 mas%, gdje se Ni kreće od 5.5 do 8.5 mas%, te gdje se N kreće od 0.28 do 0.40 mas%.
In particular, R10, R11 and R12 are as defined in (b) and/or (c). 
Najpoželjnije su R'", R'' i R'* u skladu s definicijom (b) i/ili (c).
A reduction in blood cell levels and the generation of new blood cells in the bone marrow, myelosuppression, is also a common, toxic effect of many standard chemotherapeutic drugs. 
Mijelosupresija, redukcija razine stanica u krvi i u generairanju novih krvnih stanica u koštanoj srži, je također poznata, toksični efekt mnogih standardnih kemoterapijskih lijekova.
An S1P receptor modulator or agonist compound according to claim 1 for use in the treatment of an autoimmune condition according to claim 1, wherein Compound A is used as hemifumarate salt. 
Tvar koja je modulator ili agonist SIP receptora u skladu s patentnim zahtjevom 1 za uporabu u liječenju autoimunog stanja prema patentnom zahtjevu 1, pri čemu se Tvar A koristi kao sol hemifumarat.
(See HPLC conditions below). 
(Vidjeti uvjete HPLC, niže).
Additionally, the gradual rise in rapamycin concentration associated with selected rapamycin carbohydrate derivatives may ameliorate toxic effects associated with the rapid rise in drug concentration when rapamycin itself is orally administered. 
Nadalje, postupni porast konceniracije rapamicina povezan s nekim ugljikohidratnim derivatima rapamicina može ublažiti toksične učinke povezane s brzim porastom koncentracije lijeka kad se oralno primjenjuje sam rapamicin.
an antibody which binds to the extracellular portion of a tumor-associated antigen, 
(i) _antitijelo koje se veže za ekstracelularni dio antigena koji je povezan sa tumorom,
The peptide of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 214, 196, 202, 210, 213, 217 or 223. 
Peptid u skladu s patentnim zahtjevom 1, naznačen time što se navedeni peptid sastoji od aminokiselinskog slijeda SEQ ID NO: 194, 174, 178 ili 186.
The process according to claim 1 characterised in that said organic solvent is aprotic. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što je organsko otapalo neprotonsko.
Process according to any of claims 1 to 4 in which the relevant toroidal melt flow pattern is obtained by arrangement of the submerged combustion burners at the melter bottom, in a annular burner zone, imparting a vertically upward directed speed component to the flame and combustion gases, at a distance between adjacent burners of 250 to 1250 mm, advantageously 500 to 900 mm, preferably 600 to 800, even more preferably 650 to 750 mm. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što se relevantni toroidni uzorak tečenja taline postiže razmještajem plamenika za uronjeno izgaranje na dnu talionika, u prstenastom plameničkom području, koji pridaje okomitu prema gore usmjerenu komponentu brzine plamenu i plinovima izgaranja, na udaljenosti između susjednih plamenika od 250 do 1250 mm, pogodno 500 do 900 mm, po mogućnosti 600 do 800, još poželjnije 650 do 750 mm.